In this video, we dive into a groundbreaking study published in JAMA Ophthalmology that explores the potential link between semaglutide, a popular medication for type 2 diabetes and weight loss, and the risk of developing nonarteritic anterior ischemic optic neuropathy (NAION).
Reference:
Hathaway JT, Shah MP, Hathaway DB, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol. Published online July 03, 2024. doi:10.1001/jamaophthalmol.2024.2296
Join this channel to get access to perks:
[ Ссылка ]
If you enjoyed this video and found it informative, please give it a thumbs up. For more insightful content on important health topics, don't forget to subscribe to our channel.
🔔 Subscribe here: [ Ссылка ]
Thank you for your support!
FOLLOW US:
✅Website: [ Ссылка ]
✅Instagram: [ Ссылка ]
✅Facebook: [ Ссылка ]
✅Twitter: [ Ссылка ]
Medical Disclaimer: The content presented on this channel serves informational purposes only and is not intended to replace individualized medical consultation. We strongly recommend consulting with a qualified healthcare professional for personalized medical advice before initiating any treatment or program. Utilizing any information from this channel is solely at your own risk. The SELF Principle YouTube channel, Podcast, and website are not responsible for any actions taken based on the content provided. Do not disregard or delay seeking professional medical guidance due to information obtained here.
